In this discussion, Stephen Schuster and Jason Westin from top cancer centers delve into the latest in CAR T-cell therapy for non-Hodgkin lymphoma. They explore the treatment landscape, strategies to manage toxicities, and the promise of allogeneic CAR-T products. Joining them, Stephen Ansell and Martin Hutchings share insights on the role of bispecific antibodies, comparing their efficacy against CAR T therapies. They also address unique challenges and exciting combinations with antibody-drug conjugates that could redefine treatment approaches.

Experts Stephen Ansell, Paolo Ghia, and Andrew Rawstron discuss Monoclonal B-cell lymphocytosis (MBL) as a precursor to CLL, exploring biology, classification, and early interception possibilities. They cover MBL progression, genetic similarities with CLL, B-cell receptor as an early marker, and the importance of immune system interactions for early intervention.

In this podcast, experts Stephen Ansell and Marek Trněný discuss the evolving treatment landscape in mantle cell lymphoma. They explore the impact of stem cell transplants, the emergence of novel therapies, and the importance of maintenance therapy. Different treatment approaches, including CAR T cell therapy, are also discussed along with the potential for cure and long-term survival rates.